Monument Therapeutics Logo Header


New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers.

Read the interview here.

For further information, contact:

Jenny Barnett, CEO



Richard Hayhurst/Janet Joy

E: or

Tel: +44 7711 821527

Notes to Editors:

About Monument Therapeutics

Monument Therapeutics is bringing stratified medicine to neuroscience drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.

For further information visit